Development and Application of a Transcriptomic Signature of Bioactivation in an Advanced In Vitro Liver Model to Reduce Drug-induced Liver Injury Risk Early in the Pharmaceutical Pipeline

Translation of NRF1/NRF2 -mediated liver tissue biomarkers to an in vitro assay using an advanced micropatterned co-culture system (HEPATOPAC®) with primary hepatocytes from male Wistar-Hannover rats or humans Overall design: Rat and human HEPATOPAC® cells and hepatocytes from various sources without treatment and rat and human HEPATOPAC cells dosed repeatedly with pharmaceuticals; total RNA extracted from frozen cells at various time points.